Literature DB >> 16353972

Freeze-drying of proteins from a sucrose-glycine excipient system: effect of formulation composition on the initial recovery of protein activity.

Wei Liu1, D Q Wang, Steven L Nail.   

Abstract

The purpose of this study was to investigate the effect of sucrose-glycine excipient systems on the stability of selected model proteins during lyophilization. Recovery of protein activity after freeze-drying was examined for the model proteins lactate dehydrogenase and glucose 6-phosphate dehydrogenase in a sucrose-glycine-based excipient system in which the formulation composition was systematically varied. In a sucrose-only excipient system, activity recovery of both model proteins is about 80% and is independent of sucrose concentration over a range from 1 to 40 mg/mL. When both sucrose and glycine are used and the ratio of the 2 excipients is varied, however, activity recovery decreases in a pattern that is consistent with the inhibition of activity recovery by glycine crystals, despite the presence of an adequate amount of sucrose to afford protection. Annealing of sucrose-glycine formulations causes a small but significant decrease in activity recovery relative to unannealed controls, whereas no annealing effect is observed with sucrose-only formulations. Addition of 0.01% polysorbate 80 to the formulation resulted in complete recovery of activity, irrespective of the sucrose-glycine ratio or annealing. Addition of the same concentration of polysorbate 80 to the reconstitution medium caused an increase in activity recovery for each formulation, but the overall pattern remained unchanged. The data are consistent with an interfacial model for lyophilization-associated loss of protein activity involving denaturation at a solid/freeze-concentrate interface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353972      PMCID: PMC2750526          DOI: 10.1208/pt060223

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  12 in total

1.  Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist.

Authors:  B S Chang; G Reeder; J F Carpenter
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Effect of freezing on aggregation of human growth hormone.

Authors:  B M Eckhardt; J Q Oeswein; T A Bewley
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

3.  Effect of process conditions on recovery of protein activity after freezing and freeze-drying.

Authors:  S Jiang; S L Nail
Journal:  Eur J Pharm Biopharm       Date:  1998-05       Impact factor: 5.571

4.  Surface-induced denaturation of proteins during freezing and its inhibition by surfactants.

Authors:  B S Chang; B S Kendrick; J F Carpenter
Journal:  J Pharm Sci       Date:  1996-12       Impact factor: 3.534

5.  Proteins in frozen solutions: evidence of ice-induced partial unfolding.

Authors:  G B Strambini; E Gabellieri
Journal:  Biophys J       Date:  1996-02       Impact factor: 4.033

6.  Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.

Authors:  J M Sarciaux; S Mansour; M J Hageman; S L Nail
Journal:  J Pharm Sci       Date:  1999-12       Impact factor: 3.534

7.  Development of an efficient single-step freeze-drying cycle for protein formulations.

Authors:  B S Chang; N L Fischer
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

8.  Surface characterisation of freeze-dried protein/carbohydrate mixtures.

Authors:  A Millqvist-Fureby; M Malmsten; B Bergenstâhl
Journal:  Int J Pharm       Date:  1999-11-30       Impact factor: 5.875

9.  Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.

Authors:  T Osterberg; A Fatouros; M Mikaelsson
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

10.  The effects of formulation variables on the stability of freeze-dried human growth hormone.

Authors:  M J Pikal; K M Dellerman; M L Roy; R M Riggin
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

View more
  5 in total

1.  Thiol-disulfide interchange in the tocinoic acid/glutathione system during freezing and drying.

Authors:  Mette Thing; Jun Zhang; Jennifer Laurence; Elizabeth M Topp
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

2.  Bordonein-L, a new L-amino acid oxidase from Crotalus durissus terrificus snake venom: isolation, preliminary characterization and enzyme stability.

Authors:  Karla C F Bordon; Gisele A Wiezel; Hamilton Cabral; Eliane C Arantes
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-08-13

3.  Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Authors:  Alexander Flood; Marcus Estrada; David McAdams; Yuhua Ji; Dexiang Chen
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

4.  Immunisation of Sheep with Bovine Viral Diarrhoea Virus, E2 Protein Using a Freeze-Dried Hollow Silica Mesoporous Nanoparticle Formulation.

Authors:  Donna Mahony; Karishma T Mody; Antonino S Cavallaro; Qiuhong Hu; Timothy J Mahony; Shizhang Qiao; Neena Mitter
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

5.  Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein.

Authors:  Karishma T Mody; Donna Mahony; Antonino S Cavallaro; Jun Zhang; Bing Zhang; Timothy J Mahony; Chengzhong Yu; Neena Mitter
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.